Nanjing Leads Biolabs Phase IIb EP-NEC study chosen ESMO 2026 LBA
Nanjing Leads Biolabs said its pivotal Phase IIb opamtistomig study in advanced EP-NEC was selected as a Late-Breaking Abstract and Proffered Paper at ESMO 2026. The company added that data support its NDA under NMPA priority review.